Ignite Creation Date:
2024-05-05 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00528060
Status:
COMPLETED
Last Update Posted:
2011-12-22
First Post:
2007-09-10
Brief Title:
Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada
Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Organization:
French National Agency for Research on AIDS and Viral Hepatitis
Study Overview
Official Title:
Pilot Study to Measure Exposure to Atazanavir as a Component of Pharmacokinetic Parameters and Adherence Measured With MEMS in Naive HIV-infected Patients Treated Once Daily With Atazanavir Combined to Ritonavir and to TenofovirEmtricitabine ANRS 134 Cophar 3
Status:
COMPLETED
Status Verified Date:
2011-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ANRS134COPHAR3
Brief Summary:
the trial assessed the pharmacokinetics and long term plasma exposure of the following antiretrovirals atazanavir when combined to ritonavir and the tenofoviremtricitabine fixed-dose combination All drugs will be delivered in MEMS electronic device to monitor dosing history
Detailed Description:
The trial is a phase II open label non-randomized prospective multicenter trial to assess the pharmacokinetics and long term plasma exposure of the following antiretrovirals atazanavir when combined to ritonavir and the tenofoviremtricitabine fixed-dose combination All drugs will be delivered in MEMS electronic device to monitor dosing history
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None